Last week, CMS unveiled new, voluntary changes for Medicare Part D. The new 5-year model, which CMS calls Part D Payment Modernization, will test the feasibility of shifting more risk to Medicare Advantage and Part D plans.
Last week, CMS, via its Center for Medicare and Medicaid Innovation, unveiled new, voluntary changes for Medicare Part D. The new 5-year model, which CMS calls Part D Payment Modernization, will test the feasibility of shifting more risk to Medicare Advantage (MA) and Part D plans.
Currently, when a patient spends enough on their prescription drugs to enter the catastrophic phase of the Part D benefit, which covers self-administered drugs, Medicare must pay 80% of the patients’ drug costs. According to CMS, this structure leaves plans with little incentive to negotiate for lower costs for the highest-spending patients.
In fact, between 2008 and 2017, federal spending on the Part D catastrophic phase nearly quadrupled (from $9.4 billion to $37.4 billion). In 2016, 3.2 million beneficiaries reached the catastrophic phase, and beneficiaries who did not qualify for low-income subsidies reached an average out-of-pocket drug cost of more than $3000.
Under the new model, which is open to eligible standalone prescription drug plans and MA prescription drug plans, and which will take effect in 2020, plans will take on a greater share of risk for spending in the catastrophic phase. CMS believes that this assumption of more risk will serve as an incentive for plans to encourage the use of drugs with lower list prices.
Based on plan year performance, CMS will retrospectively create a spending target for what the government would have spent without the plans assuming added risk, and participating plans will share in the savings generated if they remain below the target. Similarly, they will be accountable for losses if they overspend; participating organizations will have to repay 10% of the difference of any additional spending. The plan also introduces a Part D rewards and incentives program to provide tools by which to help enrollees choose drugs with lower costs.
CMS says that it expects that the model will maintain or improve beneficiaries’ access to affordable, necessary Part D-covered drugs.
Announcement of the Part D Modernization model dovetails with changes to MA plans that will be tested under the Value-Based Insurance Design (VBID) model in 2020. The model is intended to reduce Medicare’s expenditures while enhancing the quality of care for beneficiaries and improving healthcare service delivery.
For the year 2020, all MA plans can apply to test 1 or more of 4 offered interventions: a VBID program that reduces cost-sharing or adds benefits for enrollees based on a beneficiary’s condition or socioeconomic status; an MA and Part D rewards and incentives program; a program that increases access to telehealth services; and a required component that focuses on timely, coordinated approaches to wellness and health planning.
Requests for applications for participating in the Part D model and the VBID model will be made available by CMS this week.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.